Part the Cloud Translational (PTC) Research for Alzheimer's Disease Program: Combination Therapies Program

Program Objective:

The Alzheimer's Association is pleased to announce a dedicated Part the Cloud Translational Research Funding opportunity to advance combination clinical trials for Alzheimer's disease and related dementias (AD/ADRD). This program will support combination strategies that bring together at least two drug approaches, with optional inclusion of additional drug and or behavioral intervention components, to accelerate innovative, biomarker-informed combination therapies into clinical testing.

Background:

In today's landscape of newly approved disease-targeting therapeutics, the momentum of Alzheimer's therapeutics is more exciting than ever. Initial approvals have paved the way for new trial designs, combination strategies, and opportunities for more personalized treatment approaches. Part the Cloud (PTC) has a track record of identifying forward-looking, innovative clinical trials across diverse mechanisms of action, including dedicated funding calls focused on neuroinflammation, vascular approaches, and metabolic approaches, many of which are now represented in the broader clinical trials pipeline.

This sets a foundation for combination approaches, including drug-drug and drug/behavioral intervention combinations. PTC has funded several combination-oriented studies through its general calls, but recognizes now is the time for a dedicated focus to bring forward clinical trials (Phase 1-3) that uniquely advance combination therapies into clinical testing for AD/ADRD.

Combination therapies are increasingly represented across the Alzheimer's disease clinical pipeline. In the 2025 AD drug development pipeline analysis, there are 20 trials of combination therapies, comprising 11% (20 of 182) of current trials (Cummings et al. *TRCI* 2025). These include pharmacodynamic combinations, where both agents are expected to have pharmacologic effects, and pharmacokinetic combinations, where one agent is used to optimize the exposure or tolerability of another. Examples in the pipeline include combinations intended to address inflammation or beta amyloid pathophysiology, as well as combinations designed to improve central nervous system exposure or reduce dose-limiting peripheral adverse effects.

Despite an increase in the number of combination trials in AD/ADRD, they remain operationally and scientifically challenging. Combination strategies require clear rationale for additive or synergistic benefit, careful safety monitoring for overlapping toxicities and drug-drug interactions, and trial designs that can demonstrate biological and or clinical signals.

This funding mechanism will provide support for combination clinical trials (Phase 1-3) in AD/ADRD, including drug-drug combinations and drug plus behavioral intervention combinations. Priority will be given to proposals that: (1) test complementary mechanisms of action with strong biological rationale; (2) incorporate biomarker-based inclusion criteria and biomarker outcomes to demonstrate target engagement and or downstream biological impact; and (3) address how approved or investigational anti-amyloid monoclonal antibodies targeting beta amyloid are incorporated into, compared within, or otherwise considered in the combination strategy.

General considerations:

Applications will be accepted from academic investigators and small companies proposing Phase 1-3 (Proof of Concept) combination clinical trials in individuals with Alzheimer's disease or related dementias (including early symptomatic stages as appropriate to the intervention).

The proposed study must evaluate a combination strategy that includes at least two therapeutic approaches:

- Drug-drug, drug-behavioral intervention, drug/device, and other drug/non-pharmacological combination approaches are allowed. The rationale for the combination approach must be rigorously scientifically justified. Devices used in combinations must have been clinically validated, and with clear regulatory approval or INE (or equivalent) designation to be included in the approach.
- Investigators are strongly discouraged from using cognition as the primary outcome measure for the interventions.
- Studies must include biomarker-based inclusion criteria, if appropriate for the indication being considered, and incorporate biomarker outcomes, if appropriate for the indication being considered, suitable for assessing target engagement, pathway modulation, and/or disease biology. If therapies are intended to target Alzheimer's disease biology, inclusion criteria must be based on biomarker evidence.
- Proposals must address the role of anti-amyloid monoclonal antibody treatments within the design, including whether they are part of the combination regimen, part of standard of care and/or background therapy, an active comparator, or explicitly excluded with justification for participants in the proposed study.
- All proposals must clearly outline the study population, endpoints, statistical plan, safety monitoring, and anticipated decision criteria for advancement to subsequent development stages.

Studies funded by Part the Cloud with results justifying further development (e.g. Phase 2b, or 3) may be eligible to apply to the Alzheimer's Clinical Trials Consortium (ACTC) (U24 AG057437). ACTC provides comprehensive infrastructure and expertise on ADRD clinical trials. ACTC and the proposer will work in collaboration to develop a grant application to National Institute on Aging, NIH. If funded, ACTC will conduct the trial. Mentorship and Principal Investigator training in Alzheimer's Clinical Trials is provided by ACTC. Read more at: https://www.actcinfo.org/submit-a-proposal.

Funding and award period:

Each Phase 2-3 PTC award is limited to a total of $2,000,000 (direct and indirect costs) for a duration of two to three years. In rare instances, up to $3,000,000 may be considered, on a case-by-case basis. Phase 1 projects are limited to a total of $1,000,000 total costs. Indirect costs are only allowable for non-profit organizations, and are capped at 10 percent of total direct costs, inclusive of indirect costs for any subcontracts. For-profit organizations are not permitted indirect costs.

Detailed guidelines on allowable and not allowable costs are included below.

The Alzheimer's Association reserves the right to not allow unbudgeted expenses.

Key Dates:

LOI and application submissions must be received by 5:00 pm Eastern time by their respective deadlines. Late submissions will not be accepted - *no exceptions.*

Letter of Intent Launch	**By Mar. 12, 2026**
Letter of Intent Deadline*	**Mar, 26, 2026, 5:00 pm ET**
Application Deadline	**Apr. 30, 2026, 5:00 pm ET**
Application Review	**May – June 2026**
Award Notifications	**By July 15, 2026**

*** Note, due to the high number of submissions, specific feedback and reviewer comments are not provided at the LOI stage.**

Eligibility and Ineligibility Considerations:

To avoid disqualification, investigators are encouraged to carefully consider these eligibility and ineligibility requirements before applying. The Alzheimer's Association reserves the right to find an investigator ineligible to submit for a particular program, based on the guidelines below. This section describes general inclusion and exclusion criteria. Specific requirements and additional exclusions to eligibility are noted in some detailed competition descriptions.

- Eligibility (Applicant):
  - **The Alzheimer's Association recognizes the need to increase the number of scientists from underrepresented groups to strengthen the research enterprise for Alzheimer's and related dementia. Scientists from these groups are encouraged to apply**.
  - Applicants must be considered full-time employees based on the organization/ institution definition of full-time.
  - Applicants must hold a full-time position at their organization that is equivalent to the level of Assistant Professor or above. Postdoctoral fellows are not eligible to apply but they are able to serve on the application as key personnel.
  - The Alzheimer's Association reserves the right to request further documentation to confirm eligibility of an applicant.
  - Only one primary PI per application. Multiple PI projects are not allowed. However, collaborators may be included as key personnel on the project.
- Eligibility (Organization/ Institution):

- In general, public, private, research laboratories, medical centers, hospitals and universities are eligible to apply. For profit organizations are eligible to apply.
  - State and federal government-appropriated laboratories in the U.S. and abroad are prohibited from serving as the applicant institutions for this program. However, state and federal government scientists can participate as collaborating scientists with research teams from other eligible applicant institutions.
- For the Letter of Intent (LOI), you will be required to either of the following:
  - a W-9 that is signed and dated within the past five years by the signing official for US entities
  - a W-8 or W-8-BEN that is signed and dated within the past five years by the signing official
  - The form must include the EIN, TIN or VAT number
- For non-profit organizations (non-academic), additional documentation may be required to confirm your organization has segregation of duties between transaction execution and transaction recording.

- Ineligibility (Applicant):
  - Individuals currently enrolled as a student in an undergraduate, master or doctoral program are not eligible, regardless of prior degree status.
  - Postdoctoral fellows or staff below the rank of Assistant Professor (or equivalent) are not eligible.
  - Temporary, part time, or acting faculty are not eligible.
  - Investigators who are delinquent in reporting to the Alzheimer's Association. The Alzheimer's Association will not accept new grant applications from investigators currently awarded an Association grant who are delinquent in submitting required reports and other deliverables on active grants. Investigators that have previous Alzheimer's Association awards closed as 'Incomplete' are not eligible to apply without exception. This policy will be strictly adhered to with no exceptions.
  - Overlapping funding of more than one Alzheimer's Association grant is not allowed. Investigators with Association awards in programs from specific program announcements may still apply to a program listed in this call, but the project must be distinct from their current award. Overlap with research or clinical fellowship programs or this program are not allowed.
  - Applications that represent the same aspects of a project should not be submitted to different programs of the Alzheimer's Association. There are some exceptions so please contact grantsapp@alz.org if you have questions.
  - Current Medical and Scientific Advisory Group (MSAG) and International Research Grant Programs (IRGP) Council members of the Alzheimer's Association cannot serve as principal investigators in any award. They may serve as key personnel or collaborators, provided there is no financial benefit and/or salary allocated to them.

- Ineligibility (Organization/ Institution):
  - State and federal government-appropriated laboratories in the U.S. and abroad are prohibited from serving as the applicant institutions for this program.
  - Applications will not be accepted if the institutional official responsible for fiscal oversight of the award also serves as the Principal Investigator (PI) on the project. Additionally, no familial relationship may exist between the PI and the institutional official with fiscal authority.
  - Applicants CANNOT submit more than one proposal to any of the programs in the current grant competition—even if the proposals cover distinctly different topics (i.e. only one application is allowed regardless of the distinct areas of focus). It is allowed for members of the same team to submit different aspects of a project to different programs, as long as they are complementary and not the same project.

- Applicants may revise and resubmit an application that was previously submitted for an earlier grant cycle; however, a new LOI is required each year. A current LOI corresponding to the application year must accompany each application. Revisions of previous submissions will be treated as new applications. Efforts will be made to provide some continuity in reviews. The resubmission of an approved LOI does not guarantee that you will be invited to resubmit a full application in a future cycle. Resubmissions may be submitted to a different program in this call and still be a resubmission. Resubmissions are reviewed holistically again, and merely responding to reviewer critiques is not enough to be funded on resubmission.

Note: Alzheimer's Association grants are generally open to scientists and researchers across the globe; however, as a U.S.-based charity, the Alzheimer's Association is subject to, and complies with, U.S. law. As a result, the Alzheimer's Association cannot award, and will not award, grants in violation of applicable U.S. statutes and regulations. This means, among other things, that the Alzheimer's Association cannot, and will not, fund any individual or entity (i) that is subject to U.S. comprehensive or targeted sanctions or if awarding funding would result in a violation of such sanctions, (ii) that is on the U.S. List of Specially Designated Nationals or entities owned or controlled by such persons, or (iii) when doing so is otherwise prohibited by U.S. laws related to combating terrorism.

Letters of Intent:

LOIs are a required component of the application process. No application will be considered without an approved LOI, including resubmitted applications. LOIs must be submitted online by the stated deadline. Late submissions will not be considered. Additional details about the LOI components, review criteria and process are included below.

All LOIS will be evaluated prior to invitation to submit a full application. Only LOIs that meet specific guidelines as outlined herein will be invited to submit applications.

LOI Components:

Applicants must complete the required sections and upload any required documents. Some of these required fields are described below:

- **Principal Investigator name & contact information**
- **Lead Institution**
  - Applicant must be a full-time employee at time of submission
  - Institution/organization name must be in English
- **Current academic rank/position**
  - Must be current at the time of submission; *pending promotions are not allowed*
- **Proposal title**
- **Area of focus:** Specific options will be available from a dropdown menu
- **Brief project description (limited to 10,000 characters, including spaces)**
- **Employer Identification Number (EIN) or TIN**
  - This number must match the non-profit documentation
  - Note: This is information specific to the institution not the applicant.
- **ORCID ID**
- **Non-profit verification**
  - W-9 (US entities) signed and dated within the past five years by an authorized institutional signing official and must include the EIN number
  - W-8-BEN (non-US entities) signed and dated within the past five years by an authorized institutional signing official and must include the EIN/TIN or VAT number
  - Note: This should not contain information about the applicant
- **Biosketch**
  - For Principal Investigator only, applicants will be able to provide biosketches for other

members of the project team at the full application stage
    - The Alzheimer's Association highly recommends using the latest NIH biosketch format (excluding Section D. Scholastic Performance), but any format will be accepted. Hyperlinks are allowed in biosketch only for individual research projects.

LOI Review Criteria and Process:

LOIs will be evaluated with attention to:

- Innovation/novelty of the proposed project (especially in the context of the PI's recently funded work)
- Alignment with the research priorities of this PTC request for applications and the Alzheimer's Association
- Impact of project on Alzheimer's and all other dementia research
- Evidence of methodological rigor that addresses the research question(s) being proposed

LOIs will be reviewed by 2 or 3 reviewers with expertise in the area of the application. Due to the number of LOIs received, individual feedback or comments from reviewers will not be shared. A fraction of LOIs will be invited for full application.

If the on-line LOI is approved and invited to submit a full proposal, an email notification will be sent from Proposal Central granting access to the on-line application. The online system must be used to submit a grant application; hard copies of the application will not be accepted.

Application Details:

Following the LOI review, some of these projects are invited to submit full applications. The PI who submits the application must be the same PI who submitted the approved LOI. The application does not need to be completed in one session; a partially completed application can be saved and completed at any time before the deadline. It is imperative that you proofread your application before submission; you will not be allowed to make any changes to the application after the deadline or once applications are under review.

The application must be submitted by the receipt date/time deadline. Once submitted, you will receive a confirmation e-mail from proposalCENTRAL that your application was successfully submitted. If you do not receive a confirmation, click the Proposals tab and under the "Status" column make sure it says **Submitted** and not **In Progress** which indicates you have not yet submitted your application. It is the applicant's responsibility to make sure that the application is complete and accurate before submission. Only a single copy of an application will be accepted.

Signatures are not required at the time of submission by the Association, however, the signature page provided is for use should your institution/organization require signatures; the Association does not override any institutional policies and/or procedures. Please do not submit the signature page with your application.

Applicants may use LLMs and other generative AI tools in the preparation of their LOIs and full applications. Applicants are fully responsible for the content of their proposal, even those parts produced by an AI tool. Using one of these tools will not affect the review of your application.

Key Considerations for Proposal Development:

Applicants are encouraged to explicitly address the following elements to strengthen alignment with the Part the Cloud Translational Research for Alzheimer's Disease Program: Combination Therapies call and to support a rigorous Phase 1 to 3 combination clinical trial proposal.

- **Combination strategy and rationale for synergy or additivity**
  Clearly define the components of the combination (at least two approaches) and the scientific basis for why the combined regimen should outperform either component alone. Specify whether the strategy is primarily pharmacodynamic (two active mechanisms) or pharmacokinetic (one component improves exposure or tolerability of another).
- **Role of anti-amyloid monoclonal antibodies in the design**
  Provide a clear plan for how approved or investigational anti-amyloid monoclonal antibodies are incorporated, compared, treated as background standard of care, or excluded (with justification). Explain how this choice affects eligibility, safety monitoring, endpoints, and interpretation of signals.
- **Biomarker-informed population selection and biomarker outcomes**
  Describe biomarker-based inclusion criteria where appropriate (for example, pathology confirmation, subtype enrichment, or pathway activation), and include biomarker outcomes that demonstrate target engagement, pathway modulation, and or downstream impact on disease biology. Link each biomarker to a specific decision point in the study.
- **Trial phase fit and proof of mechanism focus**
  Justify why the proposal is appropriately positioned for Phase 1, 2 (proof of concept), or Phase 3 within the program scope, and emphasize human proof of mechanism as a core objective. If clinical efficacy is included, position it as exploratory in earlier phases and explain how the trial will still be interpretable.
- **Design features that de-risk combination trials**
  Address operational and scientific complexity up front: randomization approach, control arms, dose and schedule selection, component contribution (when feasible), and how you will attribute biological effects to the combination versus individual elements. Include clear decision criteria for advancement to later-stage development.
- **Safety, tolerability, and drug-drug interaction strategy**
  Provide a detailed safety monitoring plan tailored to overlapping toxicities, drug-drug interactions, and known liabilities of each component (and any interaction with anti-amyloid therapies if relevant). Include stopping rules and a plan for dose adjustment or staggered initiation if needed.
- **Non-pharmacological components and device readiness (if applicable)**
  If including a behavioral intervention or device, justify clinical validity and readiness. For devices, clearly state regulatory status (for example, regulatory approval or IDE or equivalent) and how device deployment will be standardized across sites.
- **Endpoints, statistical plan, and clinically meaningful interpretation**
  Define primary and secondary endpoints, analysis populations, power assumptions, multiplicity considerations, and missing data handling. Pre-specify what constitutes a biologically meaningful signal, and how results will inform the next trial (Phase 2b or Phase 3) rather than only reporting significance.
- **Milestones, go/no-go criteria, and a decision-focused timeline**
  Provide quantifiable milestones tied to measurable outcomes and include explicit go/no-go criteria aligned to biomarker and safety readouts. A clear Gantt-style timeline should show progression toward the next developmental phase and decision points.
- **Recruitment feasibility and participant diversity plan**
  Present a realistic recruitment plan with site strategy, screening flow, and retention tactics. Explicitly describe how the trial will match or exceed the diversity of the local population and how representation will be monitored and maintained during the study.
- **Team, infrastructure, and readiness to execute**
  Describe clinical trial execution capabilities, including experience with AD/ADRD trials, biomarker collection and processing, safety oversight, and any CRO or coordinating center support. Clearly define roles and decision-making structure.
- **Budget alignment and allowability**
  Ensure the budget matches the program caps and cost rules, including indirect cost limitations (non-profit only, capped) and prohibited cost categories. Align major cost drivers to trial-critical activities (biomarkers, safety monitoring, recruitment, data management).

- **Pathway to next-stage support (including ACTC readiness)**
  Explain how the proposed study will generate the evidence needed for a subsequent Phase 2b or Phase 3 effort, including potential alignment with the Alzheimer's Clinical Trials Consortium pathway if results justify expansion.

Additional details for the application process are described below:

If you are invited to submit a full application, the required materials including the application format, templates, and instructions, will be available online at proposalCENTRAL after your LOI has been approved in the system.

Full applications will not be accepted without an approved LOI from the current cycle.

- If you did not receive an email from an Alzheimer's Association staff member about your approval to submit a full application for the current cycle you should not submit an application, even if one is available in your proposalCENTRAL Account.

Applicants must complete the required sections and upload required documents as listed. Some fields are identical to the LOI. Some of these required fields are described below:

- Problem Statement – maximum 1 page.
- Work Plan – maximum 5 pages. Efficacy should not be the primary outcome for studies at phase 1 and phase 2; however, it may be an exploratory outcome. All applications should have clear Go/No Go criteria to the next phase of clinical development of the therapy and be clearly outlined in the application. The application must demonstrate how data from the proposed study will inform future trials.
- Therapeutic Rationale – maximum 1 page.
- Available Resources & Budget Justification (maximum 2 pages) – A budget justification for the proposed research project is required and must be submitted with the application and within the allowable two-page limit. However, if the application is awarded a more detailed budget will be required and must be approved before the disbursement of funds. Indicate any additional sources of complementary funding that will enhance or supplement this project's goals.
- Data Management and Sharing Plan (maximum 3 pages): The Association recommends using the amended NIH template provided. When data sharing may be limited, applicants must explain such limitations at the time of application.
- Detailed Milestone Plan and Timeline (e.g. Gantt Chart) (maximum 3 pages): Clearly delineate project stages and milestones, specifying critical decision points and go/no-go criteria. Milestones must be quantifiable and tied to specific, measurable outcomes. Include anticipated timeframes for each milestone, clearly showing progression toward IND submission or next developmental phase.
- Recruitment Plan - 1 page. The Association expects all trials to match or exceed the diversity of their local population at a minimum. **Any funded study must maintain representation of the community the study is being conducted.**
- Research Project Team Qualifications and Roles (maximum 5 pages): Provide detailed information about the Principal Investigator(s), co-investigators, and collaborators. Outline the experience, expertise, and previous success relevant to drug discovery and development, Alzheimer's research, regulatory processes, and commercialization. Clearly define roles, responsibilities, and interactions among team members, consultants, and CROs (if applicable).
- Reference and Citations – maximum 1 page.

Budget Considerations: It is required that most of the funds awarded under this program be used for direct research support. For non-profit organizations, no more than 10% of the total direct costs may be included as indirect costs; this is inclusive of indirect costs for the implementing institution as well as

any subcontracts. For-profit organizations may not include any indirect costs.

- Direct costs allowed:
  - Purchase and care of laboratory animals
  - Small pieces of laboratory equipment and laboratory supplies
  - Purchases over $10,000 require prior approval, even if included in the project proposal budget
  - Computer software if used strictly for data collection (requires prior approval)
  - Salary for the principal investigator, scientific (including postdoctoral fellows) and technical staff (including laboratory technicians and administrative support directly related to the funded grant); there is no salary cap
  - Costs associated with the management and sharing of research data
  - Costs associated with contract research organizations (CROs)
  - Support for travel to scientific and professional meetings and additional support for travel expenses necessary to carry out research planned – this may include site visits. A total of $12,500 over a three year period may be requested for travel purposes and is not to exceed $7,000 in any given year. If you request the full $12,500 towards just two years of travel and are requesting a three year award you will not be able to request travel funds for one of those years.
  - Remuneration for human volunteers should follow the recommendations proposed by the National Alzheimer's Coordinating Center (NACC) located here: https://files.alz.washington.edu/documentation/remuneration-guidelines.pdf
  - Travel expenses for projects involving human volunteers are allowable expenses not included in the travel above. This can be captured under other expenses (itemized) in the budget.

- Direct costs *not* allowed:
  - Computer hardware or standard software (e.g. Microsoft Office, mouse monitor, computer parts, AppleCare)
  - Laboratory equipment such as freezers, ultracentrifuges, RT-PCR machine, microscopy/imaging equipment
  - Service contract fees of equipment
  - Construction or renovation costs
  - Tuition
  - Rent for laboratory/office space
  - Visa costs and fees
  - Expenses such as Data Network Recharges and Computing and communication device support services. However, data sharing and/or data storage for imaging, sequencing and other study data is allowed.
  - General liability insurances, such as GAEL
  - Wire and currency exchange fees; it is important to note that the Association does not adjust total funded amount in relation to fluctuations in exchange rates. All grants are paid in U.S. dollars.
  - Institutional overheads associated with staff time
  - The Alzheimer's Association Medical and Scientific Advisory Group (MSAG), the International Research Grant Program (IRGP) Council members and current employees of the Alzheimer's Association are allowed to be key personnel or collaborators on projects, however they are NOT ALLOWED to receive any salary or compensation. A complete list of MSAG and IRGP Council members can be found on our website alz.org/grants.
  - The Alzheimer's Association reserves the right to decline any charge that is an institutional fee and/or service charge.

Application Review Criteria and Process:

All applications are subject to a multiple stage peer-review process carried out with an online system. This multi-stage process is central to the Alzheimer's Association's award decisions and is designed to ensure both scientific rigor and fairness in the review of all submitted applications.

In the first stage, applications are reviewed and rated by peer scientists with expertise in the proposed area of research. Applicants may include recommended reviewers and have the option to exclude specific reviewers from evaluating their application if a conflict of interest exists. Conflicts of interest include (but are not limited to):

- The Applicant trained with/ by the reviewer.
- The reviewer published with the Applicant in the last four ~~(4)~~ years. This excludes workshop or large consortia (i.e. ADNI, IGAP, etc.)
- The reviewer has been a co-investigator on a grant application or award with the Applicant in the last four (4) years.
- The reviewer has a conceptual difference of opinion with the Applicant that will prevent a fair review.
- The reviewer will receive financial benefit from the Applicant receiving an award.

In stage one of review, each application will be evaluated with the following criteria:

- Significance of the question and/or approach being studied and rationale of the target being pursued
- Applicant information – including the training of the PI insofar as it enables them to perform the work proposed, qualifications of the collaborators, and the expertise they bring to the project.
- Quality of the proposed work plan/trial design – including novelty and innovation of the proposed project and overall study design; additionally, projects that involve human volunteers will be evaluated on planned recruitment efforts. Projects must demonstrate a clear path forward if the trial is successful.
- Quality and adequacy of available resources and budget
- Impact-risk of the proposal and how it will add to the field's overall knowledge and advancement

The second stage includes further review and discussion of the scores and comments resulting from the initial review process to normalize across reviews and programs. The second review is carried out by a select panel of representatives from the International Research Grant Program (IRGP) Council members and invited review committee members to ensure fairness and balance in the initial review procedures and to make funding recommendations to the Association.

Final recommendations from the IRGP Council are shared with the Medical and Scientific Advisory Group (MSAG) and with the Alzheimer's Association for final approval. Members of the IRGP Council and MSAG are internationally recognized experts with distinguished careers in Alzheimer's and related dementia.

Financial Responsibility:

Funding is awarded to the institution and/or organization, not to the individual principal investigator. The principal investigator or a first-degree relative cannot be listed as the signing official or financial officer, or have checks sent to their attention if awarded.

Appeals of Scientific Peer Review:

To maintain a fair and rigorous review system, the Alzheimer's Association has a process for appeal of funding decisions. Appeals will not be considered for the letter of intent stage. Regarding applications, an appeal is intended to address extraordinary circumstances.

Appropriate reasons for initiating an appeal might include:
- Evidence that a reviewer has an undeclared conflict of interest.
- An egregious error or misunderstanding in the review process.
- Active malfeasance or demonstrable lack of due diligence.

The appeal process is not intended to provide a mechanism for routine protest of failure to receive a grant. It is anticipated that funding through the Alzheimer's Associations grant programs will be extremely competitive and is limited by availability of funds.

If an applicant believes an extraordinary circumstance has contributed to failure to receive funding, the principal investigator may send a two-page, double-spaced formal letter of appeal (Word document) to grantsappeals@alz.org. Any supporting documents included must be submitted as a PDF. Appeals must be submitted within two weeks from the date your application outcome notification is sent. Notification of action on the appeal will be made via email, usually within 90 days of the appeal deadline.

Reporting Requirements, if Funded:

For funded awards through this program, there will be required scientific and financial reporting. Interim Scientific & Financial Reports must be submitted at the end of each reporting period as long as the grant remains active. Final Scientific & Financial Reports must be filed within 90 days of the grant's end date. All reports must be submitted electronically via proposalCENTRAL. The Financial Report must be approved and signed by someone with financial authority in the Office of Research and Sponsored Programs or Grants & Contracts Office at the recipient's institution. Unobligated funds remaining at the end of the award must be returned to the Alzheimer's Association.

Note: The continuation of the grant over the awarded duration is contingent upon the timely receipt of all required reports.

In addition, while animal welfare and human volunteer ethical assurances are not required at the time of application, investigators have until their chosen start date (within 6 months or less of award notification) to submit these approved documents. The Alzheimer's Association encourages investigators to initiate their certification applications on a schedule that recognizes that rDNA certification, IRB/IACUC approval at many institutions can take more than 90 days. The Association accepts only certifications that apply specifically to the funded project and must include the name of the awardee.

Projects involving human volunteers must address the appropriate inclusion or exclusion of individuals in the proposed research project and describe recruitment efforts to represent the community in which the study is planned or being conducted. Prior to distribution of funding, the researcher must provide a description of their recruitment plan, including an outline describing how their recruitment efforts will ensure representative diversity in their volunteers. This will be tracked throughout the duration of the grant.

Electronic copies of publications, presentations and abstracts that report research supported by funds from the Alzheimer's Association must be submitted electronically at the time of publication. These copies will become part of the official file of the grant and will be provided to the Communications Division of the Alzheimer's Association to assist in the efforts to further inform the public about the International Research Grant Program of the Association. Any intellectual property disclosures resulting from the award must be submitted electronically at the time of publication. The Alzheimer's Association may request any of the research outputs listed here from any awardee up to 7 years following the end of the award.

U.S. Sanctions:

Alzheimer's Association grants are generally open to scientists and researchers across the globe; however, as a U.S.-based charity, the Alzheimer's Association is subject to, and complies with, U.S. law. As a result, the Alzheimer's Association cannot award, and will not award, grants in violation of applicable U.S. statutes and regulations. This means, among other things, that the Alzheimer's Association cannot, and will not, fund any individual or entity (i) that is subject to U.S. comprehensive or targeted sanctions or if awarding funding would result in a violation of such sanctions, (ii) that is on the U.S. List of Specially Designated Nationals or entities owned or controlled by such persons, or (iii) when doing so is otherwise prohibited by U.S. laws related to combating terrorism.

Nondiscrimination and Harassment Statement:

The Alzheimer's Association is committed to providing an environment free from harassment and discrimination. The Alzheimer's Association strictly prohibits harassment and discrimination based on race; creed; color; religion; sex; sexual orientation; national origin; ancestry; age; Veteran status; citizenship status; marital status; physical or mental disabilities; pregnancy, gender identity or expression (including transgender status); genetic information; and any other characteristic protected by federal, state, or local law.

Contact Information:

For any inquiries or additional information, please contact a member of the Alzheimer's Association Grants staff at grantsapp@alz.org.

Made possible through the generous funding from Part the Cloud, benefiting the Alzheimer's Association.